ESR2 and breast cancer: As shown in Figure 2A and Supplementary Figure 2, downregulation of ERβ prevented the cisplatin-induced expression of these genes, indicating that ERβ contributes to activation of wild-type p53 in response to genotoxic stress in luminal breast cancer cells.